<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1596181</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1596181</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Deciphering the role of myofibroblasts in microvascular invasion of hepatocellular carcinoma</article-title>
<alt-title alt-title-type="left-running-head">Liu et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1596181">10.3389/fphar.2025.1596181</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xiang</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Jiangyang</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Lijia</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Qiao</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fan</surname>
<given-names>Tianbo</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2996422/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
</contrib-group>
<aff>
<institution>Department of Radiology</institution>, <institution>The Fourth Hospital of Hebei Medical University</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/342067/overview">Zhenhua Chen</ext-link>, Jinzhou Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/476407/overview">Zhijie Xu</ext-link>, Central South University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1706269/overview">Enchun Li</ext-link>, Zhejiang University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2756658/overview">Xinyu Gu</ext-link>, Henan University of Science and Technology, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Qi Wang, <email>ja1109w@hebmu.edu.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1596181</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>03</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Liu, Pan, Wang, Xie, Fan and Wang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Liu, Pan, Wang, Xie, Fan and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Hepatocellular carcinoma (HCC) often exhibits microvascular invasion (MVI), a feature with unclear mechanisms. Therefore, it is crucial to resolve its related cellular populations and molecular networks using single-cell analysis.</p>
</sec>
<sec>
<title>Methods</title>
<p>Both single-cell RNA sequencing (scRNA-seq) and RNA-seq data for HCC were obtained from public databases. ScRNA-seq data were clustered and annotated using Seurat. DAVID, CellChat, and Monocle 2 were used for scRNA-seq functional enrichment analysis, intercellular communication analysis, and cell trajectory analysis, respectively. We further assessed key gene expression in HCC cell lines and examined their effects on cell functions using CCK-8, scratch, and transwell assays.</p>
</sec>
<sec>
<title>Results</title>
<p>The HCC ecosystem comprising myofibroblasts (MFs), hepatocytes, proliferative hepatocytes, endothelial cells, dendritic cells, proliferative NK/T cells, plasma B cells, and macrophages was revealed. MFs showed the greatest difference between MVI-absent and MVI-present patients and were subdivided into five clusters. Key genes for angiogenesis are overexpressed in MF2 cells and enriched in the pathways of angiogenesis, cell migration, cell proliferation, and signal transduction. Pseudotime analysis revealed MF2 cells from MVI-present patients clustered at the terminal state and positively correlated with angiogenesis. <italic>CAMK2N1</italic> in the markers of MF2 cells was significantly associated with advanced M stage and poor prognosis. Further cellular assays showed that <italic>CAMK2N1</italic> expression was downregulated in HCC cells, and its knockdown increased the proliferation, migration, and invasion levels of cancer cells.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study highlighted the role and potential mechanism of MFs in promoting MVI formation and provides a potential marker for HCC prognosis among MF markers.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Hepatocellular carcinoma</kwd>
<kwd>microvascular invasion</kwd>
<kwd>single-cell RNA sequencing analysis</kwd>
<kwd>myofibroblasts</kwd>
<kwd>intercellular communication</kwd>
<kwd>cell differentiation</kwd>
<kwd>prognostic markers</kwd>
</kwd-group>
<counts>
<page-count count="13"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-related death worldwide (<xref ref-type="bibr" rid="B10">Chandarana et al., 2024</xref>; <xref ref-type="bibr" rid="B42">Wang et al., 2023</xref>). Risk factors associated with HCC include hepatitis B and C infections, non-alcoholic fatty liver disease, and alcoholic liver disease. Regardless of the underlying cause, the end result is liver fibrosis and cirrhosis, which eventually progress to cancer (<xref ref-type="bibr" rid="B2">Alawyia and Constantinou, 2023</xref>; <xref ref-type="bibr" rid="B3">Bansal et al., 2024</xref>). In recent years, anti-angiogenic therapies such as sorafenib, lenvatinib, and bevacizumab combined with atezolizumab have been widely used in advanced HCC, targeting VEGF/VEGFR and other angiogenic pathways to inhibit tumor vascularization (<xref ref-type="bibr" rid="B17">Finn et al., 2020</xref>; <xref ref-type="bibr" rid="B26">Kudo et al., 2019</xref>; <xref ref-type="bibr" rid="B6">Bruix et al., 2017</xref>). However, clinical resistance is common, driven by tumor heterogeneity, compensatory angiogenic signaling, and immune microenvironment adaptation (<xref ref-type="bibr" rid="B15">Federico et al., 2022</xref>). Moreover, the lack of reliable biomarkers and limited understanding of stromal cell-mediated angiogenesis restrict therapeutic precision (<xref ref-type="bibr" rid="B40">Tao et al., 2020</xref>). These limitations highlight the need to explore cellular mechanisms underlying angiogenesis in HCC, especially those contributing to microvascular invasion (MVI), which is closely linked to poor prognosis.</p>
<p>HCC, as a multi-vascular malignancy, frequently exhibits histological features of MVI (<xref ref-type="bibr" rid="B38">Sun et al., 2023</xref>; <xref ref-type="bibr" rid="B8">Cao et al., 2023</xref>). MVI includes a variety of microvascular structures, including small thin-walled vessels in the tumor capsule or adjacent fibrotic nonneoplastic liver, and thicker muscularized vessels as peripheral branches of portal veins, hepatic arteries, or hepatic veins (<xref ref-type="bibr" rid="B22">Hwang et al., 2023</xref>; <xref ref-type="bibr" rid="B18">Gouw et al., 2011</xref>). Clinical MVI imaging showed capsule rupture, irregular tumor margins, peritumoral enhancement, multifocal tumors, increased tumor size, and increased glucose metabolism on positron emission tomography-computed tomography (<xref ref-type="bibr" rid="B41">Unal et al., 2016</xref>). A systematic review study showed that the prevalence of MVI in HCC patients ranged from 15% to 57.1% (<xref ref-type="bibr" rid="B36">Rodriguez-Peralvarez et al., 2013</xref>). MVI has been clinically recognized as a prognostic factor for HCC after surgical treatment (<xref ref-type="bibr" rid="B48">Zhou et al., 2022</xref>). It should be noted, however, that the prognostic value of MVI varies with invasiveness (<xref ref-type="bibr" rid="B31">Nitta et al., 2019</xref>). In addition, the lack of definition and grading of MVI and reported inter-observer or intra-observer differences lead to great heterogeneity in the evaluation of this histological feature of HCC (<xref ref-type="bibr" rid="B36">Rodriguez-Peralvarez et al., 2013</xref>). Therefore, there is an urgent need to clarify this issue.</p>
<p>Single-cell analysis is promising as a means of understanding the heterogeneity of this unique histological feature and its relationship with HCC disease development (<xref ref-type="bibr" rid="B44">Xiao et al., 2019</xref>; <xref ref-type="bibr" rid="B51">Zulibiya et al., 2023</xref>). Currently, researchers have found, based on single-cell analysis, that tumor cells can reprogram CD10&#x2b;ALPL &#x2b; neutrophils through the NAMPT-NTRK1 signaling axis, leading to immune resistance and HCC progression (<xref ref-type="bibr" rid="B30">Meng et al., 2023</xref>). In this study, we analyzed the single-cell RNA sequencing (scRNA-seq) data of patients with MVI present and two patients with MVI absent to reveal the complex cell population of HCC patients with MVI present, the protagonist population of myofibroblasts promoting MVI, and the molecular network that interacts with hepatocytes. Finally, the markers of the main population of myofibroblasts promoting MVI were subjected to RNA-seq analysis from the The Cancer Genome Atlas (TCGA) dataset to identify candidate targets that may be potentially indicative of HCC prognosis. This approach enables the resolution of cellular heterogeneity that is often masked in bulk tissue analysis, allowing for the identification of rare but functionally significant cell subsets involved in MVI. By mapping cell-specific gene expression and trajectory, single-cell analysis provides a precise framework for decoding histological complexity in HCC.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Searching for and preprocessing scRNA-seq data for human HCC</title>
<p>ScRNA-seq data of HCC patients were downloaded from NCBI with the search number GSE242889, including three patients with MVI present and two patients with MVI absent. None of the patients had significant metastasis, and they had not yet been treated. The downloaded scRNA-seq data were loaded into the &#x201c;Seurat&#x201d; package (<xref ref-type="bibr" rid="B7">Butler et al., 2018</xref>) and read using the Read10X function. Only cells with the proportion of mitochondrial genes &#x3c;25% and the number of genes between 200 and 5000 were intercepted and normalized using the SCTransform function. The &#x201c;Harmony&#x201d; package (<xref ref-type="bibr" rid="B25">Korsunsky et al., 2019</xref>) was used for the elimination of batch effects between samples. The RunPCA function was used to perform principal component analysis (PCA) in Seurat, selecting the top 20 principal components, and the FindNeighbors and FindClusters functions were used to conduct cell clustering. According to the markers in the CellMarker2.0 database, the cell identity was identified and projected on UMAP. The cell identity was identified according to the markers contained in the CellMarker2.0 database (<xref ref-type="bibr" rid="B21">Hu et al., 2023</xref>) and projected on the UMAP.</p>
</sec>
<sec id="s2-2">
<title>Differential expression analysis based on scRNA-seq data</title>
<p>The FindAllMarkers function was used to perform differential expression analysis between determined cell clusters in Seurat. For differentially expressed genes (DEGs), it must be in accordance with only.pos &#x3d; TRUE, min.pct &#x3d; 0.25, logfc.threshold &#x3d; 0.25, and p &#x3c; 0.05 (<xref ref-type="bibr" rid="B45">Xu et al., 2024</xref>).</p>
</sec>
<sec id="s2-3">
<title>Gene Ontology (GO) functional enrichment analysis</title>
<p>Specific genes were uploaded to the DAVID database (<xref ref-type="bibr" rid="B13">Dennis et al., 2003</xref>; <xref ref-type="bibr" rid="B43">Wang et al., 2025</xref>), which can correlate genes from the input list to biological annotations. The Functional Annotation Chart was selected in Shortcut to DAVID Tools to perform GO functional enrichment analysis, and the annotated results were presented in the form of bar charts.</p>
</sec>
<sec id="s2-4">
<title>Analysis of intercellular communication</title>
<p>The CellChat package (<xref ref-type="bibr" rid="B24">Jin et al., 2021</xref>) is a versatile and easy-to-use toolkit for inferring, analyzing, and visualizing intercellular communication from any given scRNA-seq data. The CreateCellChat function was applied to create objects in CellChat, while identifyOverExpressed Genes and identifyOverExpressedInteractions were employed to identify overexpressed ligand&#x2013;receptor (LR) pairs of cell subsets. The projectData function projected gene expression data onto the protein&#x2013;protein interaction (PPI) network. The communication probability was calculated by the computeCommunProb function and displayed as a bubble plot by the netVisual_bubble function.</p>
</sec>
<sec id="s2-5">
<title>Cell trajectory analysis</title>
<p>Monocle 2 (<xref ref-type="bibr" rid="B35">Qiu et al., 2017</xref>) inferred the evolution of cells during development by conducting pseudotime analysis based on the changes in gene expression levels of cell subsets over time. In brief, the newCellDataSet function was used to construct the objects, and the highly expressed DEGs in the cell cluster were calculated by the FindAllMarkers function and submitted to reduceDimension for dimensionality reduction. Monocle 2 generated a tree-like structure after completing pseudotime modeling.</p>
</sec>
<sec id="s2-6">
<title>Calculation of the activity degree of specific gene sets in cells</title>
<p>The gene lists of angiogenesis and TGF&#x3b2; signaling pathways in hallmark were downloaded from the MsigDB database and entered into AUCell together with the single-cell expression matrix to calculate the enrichment scores of gene subsets in each cell, with higher scores indicating higher enrichment of gene subsets in the cell.</p>
</sec>
<sec id="s2-7">
<title>Acquisition of RNA-seq data</title>
<p>The TCGA-HCC cohort was selected from the public cancer genomics resource UCSC Xena to download the gene expression data of HCC genomes, and the gene expression value log2(FPKM&#x2b;1) was obtained. The cohort also provided clinical follow-up data of HCC, including TNM stage and survival data, which were also included in the analysis.</p>
</sec>
<sec id="s2-8">
<title>Cell culture and intervention</title>
<p>Human liver immortalized cells THLE-2 (C5664) and HCC cell lines Huh-7 and HepG2 were all purchased from Baidi Biotech Ltd. (Hangzhou, China) and BeiNa Culture Bio (Xinyang, China) and cultured in Roswell Park Memorial Institute-1640 medium (90023, Solarbio LifeSciences, Beijing, China) and high-glucose Dulbecco&#x2019;s modified Eagle&#x2019;s Medium (C3260, Solarbio LifeSciences). The culture media were additionally supplemented with 10% bovine calf serum (S9020, Solarbio LifeSciences) and 1% penicillin&#x2013;streptomycin (P1400, Solarbio LifeSciences). All cells were authenticated via short tandem repeat (STR) genotyping recently, tested negative for <italic>mycoplasma</italic> contamination, and cultured in an incubator (3311, ThermoFisher, Waltham, MA) at 37&#xb0;C with 5% CO<sub>2</sub>.</p>
<p>For the knockdown assay, the small interfering RNA specific to <italic>CAMK2N1</italic> and the control small interfering RNA were all synthesized and purchased from GenePharma (Shanghai, China). Thereafter, the Lipofectamine 2000 transfection reagent (11668027, ThermoFisher) was applied for the transfection as per the manuals provided by the manufacturer. All cells were harvested after 48&#xa0;h and used in the subsequent assays. The target sequences for small interfering RNA specific to <italic>CAMK2N1</italic> are 5&#x2032;-CGG&#x200b;GTT&#x200b;GTT&#x200b;ATT&#x200b;GAA&#x200b;GAT&#x200b;GAT&#x200b;AG-3&#x2032; (si-<italic>CAMK2N1</italic>&#x23;1) and 5&#x2032;-GGG&#x200b;TTG&#x200b;TTA&#x200b;TTG&#x200b;AAG&#x200b;ATG&#x200b;ATA&#x200b;GG-3&#x2032; (si-<italic>CAMK2N1</italic>&#x23;2).</p>
</sec>
<sec id="s2-9">
<title>Scratch test</title>
<p>The scratch test was adopted to evaluate the migration of HCC cells. In detail, transfected HCC cells in these two groups were seeded in a 6-well plate at a density of 1 &#xd7; 10<sup>5</sup> cells/well and received a scratch on the monolayer via a 10-&#x3bc;L pipette tip once they grew fully confluent. After culturing for 48&#xa0;h, the cell debris was removed, and the cell residue was visualized under the optical microscope (DP27, Olympus, Tokyo, Japan). The wound closure (%) was accordingly calculated to reflect the migration status of cells in both groups.</p>
</sec>
<sec id="s2-10">
<title>Transwell assay</title>
<p>For the Transwell assay to determine the invasion of HCC cells, a Transwell system with a pore size of 8&#xa0;&#x3bc;m (3422, Corning, Inc., Corning, NY) was applied. Specifically, the upper chamber was filled with HCC cells and the non-serum culture media (final volume: 200&#xa0;&#x3bc;L) and coated with matrix gel (M8370, Solarbio LifeSciences) in advance. Thereafter, HCC cells were routinely cultured for 48&#xa0;h, following which the uninvaded cells in the upper chamber were removed carefully with a cotton swab. Those cells that migrated to the lower chamber were accordingly fixed in 4% fixative (P1110, Solarbio LifeSciences) for 15&#xa0;min and stained using 0.1% crystal violet (G1063, Solarbio Lifesciences) for 15&#xa0;min. All cells were also visualized under the same optical microscope used for the scratch test (<xref ref-type="bibr" rid="B47">Zhang et al., 2024</xref>).</p>
</sec>
<sec id="s2-11">
<title>Reverse-transcription quantitative PCR</title>
<p>All cellular total RNA was extracted with TRIzol reagent (15596026, ThermoFisher), and the concentration was determined in a spectrophotometer (ND-2000, ThermoFisher). Subsequently, the complementary DNA was synthesized with a relevant assay kit (6110A, Takara, Shiga, Japan) and applied to the PCR process. A specific assay kit (204243, Qiagen, Hilden, Germany) and the ABI7500 thermocycling system (ThermoFisher) were both used to run the PCR at these parameters: 95&#xb0;C for 15&#xa0;min, followed by 94&#xb0;C for 15&#xa0;s, 60&#xb0;C for 30&#xa0;s, and 72&#xb0;C for 30&#xa0;s for 40 repeated cycles. The mRNA levels were finally calculated based on formula 2<sup>&#x2212;&#x394;&#x394;c(t)</sup> with GAPDH as the reference gene (<xref ref-type="bibr" rid="B28">Livak and Schmittgen, 2001</xref>).</p>
<p>The primers applied are:</p>
<p>
<italic>CAMK2N1</italic>: forward: 5&#x2032;-GGA&#x200b;CAC&#x200b;CAA&#x200b;CAA&#x200b;CTT&#x200b;CTT&#x200b;CGG&#x200b;C-3&#x2032;; reverse: 5&#x2032;-GTC&#x200b;GGT&#x200b;CAT&#x200b;ATT&#x200b;TTT&#x200b;CAG&#x200b;CAC&#x200b;GTC-3&#x2032;</p>
<p>GAPDH: forward: 5&#x2032;-GTC&#x200b;TCC&#x200b;TCT&#x200b;GAC&#x200b;TTC&#x200b;AAC&#x200b;AGC&#x200b;G-3&#x2032;; reverse: 5&#x2032;-ACC&#x200b;ACC&#x200b;CTG&#x200b;TTG&#x200b;CTG&#x200b;TAG&#x200b;CCA&#x200b;A-3&#x2032;</p>
</sec>
<sec id="s2-12">
<title>Statistical analysis</title>
<p>All statistical analysis and visualization were performed using R software (version 4.3.1) and GraphPad Prism software (version 8.0.2). The difference of continuous variables between the two groups was tested by the Wilcoxon rank sum test, analysis of variance and Student&#x2019;s t-test, and the correlation was measured by Pearson correlation analysis. Grouping before survival analysis was based on the median of gene expression values, and survival differences were calculated by the log-rank test. The threshold of statistical significance was set at <italic>p</italic> &#x3c; 0.05 for statistical tests without a specified p-value.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Cellular heterogeneity between HCC patients with MVI absent and MVI present</title>
<p>Cluster analysis and annotation of 9,828 cells in HCC patients with MVI absent and 13,402 cells in HCC patients with MVI present identified eight major cell types: they were myofibroblasts (MFs), hepatocytes, proliferative hepatocytes, endothelial cells, dendritic cells, proliferative NK/T cells, plasma B cells, and macrophages (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>). Apolipoprotein APOE, transporter TTR, and the acute-phase proteins fibrinogen &#x3b2; (FGB) and haptoglobin (HP) were significantly overexpressed in both hepatocytes and proliferative hepatocytes (<xref ref-type="bibr" rid="B12">Dayoub et al., 2017</xref>). However, proliferative hepatocytes specifically expressed the proliferation-related markers <italic>MKI</italic> and <italic>TOP2A</italic> relative to proliferative hepatocytes. <italic>CD163</italic>, <italic>AIF1</italic>, and <italic>C1QAM2</italic> were significantly overexpressed in macrophages, all of which were related markers of M2 macrophages (<xref ref-type="bibr" rid="B49">Zhu et al., 2022</xref>). The high expression of <italic>NKG7</italic> and <italic>CD3D</italic> specifically distinguishes proliferative NK/T cells from other cells. The DEGs for identifying plasma B cells were <italic>JCHAIN</italic> and <italic>MZB1</italic> (<xref ref-type="bibr" rid="B20">Hensvold et al., 2023</xref>). The identity of MFs was confirmed based on the expression levels of <italic>BGN</italic>, <italic>COL3A1</italic>, <italic>TAGLN</italic>, and <italic>ACTA2</italic>. Dendritic cells specifically expressed <italic>CLEC9A</italic> and <italic>WDFY41</italic>, which are essential components for antigen cross-presentation in these cells (<xref ref-type="bibr" rid="B32">Ohara and Murphy, 2023</xref>) (<xref ref-type="fig" rid="F1">Figures 1C,E</xref>). The largest difference in the proportion between MVI-absent patients and MVI-present patients was MFs, which accounted for a higher proportion in MVI-present patients (<xref ref-type="fig" rid="F1">Figure 1D</xref>). This abnormal distribution of cells sent a message that MFs may play a role in the MVI of patients with HCC.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Cellular heterogeneity between HCC patients with MVI absent and MVI present. <bold>(A)</bold> UMAP diagram of cells in MVI-absent patients after clustering and annotation. <bold>(B)</bold> UMAP diagram of cells in MVI-present patients after clustering and annotation. <bold>(C)</bold> Dot plot of the DEG expression in each type of cell. <bold>(D)</bold> Percentage of each type of cell in HCC patients with MVI absent and MVI present. <bold>(E)</bold> Cell type-specific gene expression patterns.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g001.tif">
<alt-text content-type="machine-generated">UMAP plots and graphs detailing cell types and gene expression in samples with and without MVI. Panels A and B show cell types in UMAP plots labeled as myofibroblasts, hepatocytes, proliferative hepatocytes, endothelial cells, dendritic cells, macrophages, proliferative plasma B cells, and NK/T cells. Panel C is a dot plot showing average expression levels of genes, with bubble size indicating the percentage of cells expressing each gene. Panel D is a bar graph comparing the percentages of different cell types between MVI absent and present samples. Panel E contains UMAP plots showcasing expression levels of specific genes marked in red.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-2">
<title>Classification and characterization of MFs in HCC patients with MVI present</title>
<p>Because of the large difference in the proportion of MFs between HCC patients with MVI absent and those with MVI present, we proceeded to characterize this population in detail, focusing on the subgroup and gene expression profiles, intercellular communication networks, and differentiation trajectories of this population. The MFs were further divided into five clusters by cell clustering (<xref ref-type="fig" rid="F2">Figure 2A</xref>). The proportions of MF2 and MF5 cells were significantly higher in HCC patients with MVI present than in those with MVI absent (<xref ref-type="fig" rid="F2">Figure 2B</xref>). MF2 cells specifically expressed liver fibrosis-related genes <italic>AGTR1</italic>, <italic>CYGB</italic>, <italic>PIEZO2</italic>, and <italic>LPL</italic>, and MF5 cells specifically highly expressed immune-related genes <italic>TRAC</italic>, <italic>CD3D</italic>, <italic>GZMB</italic>, and <italic>FCGR3A</italic> (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Among the annotated biological processes, MF2 cells were linked with signal transduction, positive regulation of cell proliferation, extracellular matrix organization, angiogenesis, and cell migration (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Meanwhile, MF5 cells could be linked with adaptive immune response, innate immune response, and inflammatory response (<xref ref-type="fig" rid="F2">Figure 2E</xref>). Therefore, MF2 cells were closely related to the promotion of angiogenesis, while MF5 cells were mainly related to the recruitment and activation of immune cells. Angiogenesis is one of the important mechanisms in the formation of MVIs. Most of the angiogenesis key genes were overexpressed in MF2 cells and underexpressed in MF5 cells (<xref ref-type="fig" rid="F2">Figure 2F</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Classification and characterization of MFs in HCC patients with MVI present. <bold>(A)</bold> Cluster UMAP diagram of MFs. <bold>(B)</bold> Distribution of proportions of the five clusters of MFs in MVI-absent and MVI-present patients. <bold>(C)</bold> The dot plot shows the mean expression level of DEGs for each MF cluster. <bold>(D)</bold> Biological processes that were significantly enriched for highly expressed DEGs in MF2 cells. <bold>(E)</bold> Biological processes that were significantly enriched for highly expressed DEGs in MF5 cells. <bold>(F)</bold> Expression levels of key genes of angiogenesis in each MF cluster.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g002.tif">
<alt-text content-type="machine-generated">Panel A shows a UMAP plot clustering data points into five groups labeled MF1 to MF5. Panel B is a bar chart comparing the percentage presence and absence of MVI across MF1 to MF5. Panel C is a dot plot illustrating gene expression levels, with larger dots indicating higher expression. Panel D is a bar chart presenting biological processes in MF2, with data colored based on p-value. Panel E is a bar chart detailing immune response processes in MF5, with varying p-values. Panel F is a dot plot of gene expressions related to angiogenesis, differentiated by color and dot size.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-3">
<title>Potential LR pairs that mediate communication between MF2 cells and hepatocytes</title>
<p>By analyzing the LR pairs of communication between MF2 and hepatocytes in HCC patients with MVI absent and MVI present, it was found that direct contact LR pairs, including OCLN-OCLN, JAG1-NOTCH3, CDH5-CDH5, CD99<sup>&#x2212;</sup>CD99, and APP-CD74, were involved in mediating the communication between MF2 cells and hepatocytes in both HCC patients with MVI absent and MVI present. The difference was that the communication between MF2 cells and hepatocytes in MVI-present patients was also mediated by THY1 (ITGAX &#x2b; ITGB2), THY1- (ITGAM &#x2b; ITGB2), JAG1-NOTCH1, ITGB2-ICAM1, EFNA5-EPHA3, EFNA5-EPHA2, and EFNA5-EPHA1 (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). In addition to the direct contact type LR pairs, secretory LR pairs were also involved in the communication between MF2 cells and hepatocytes and were more complex in MVI-present patients. TNFSF12-TNFRSF12A, TGFB2-(TGFBR1&#x2b;TGFBR2), TGFB2-(ACVR1B &#x2b; TGFBR2), TGFB2-(ACVR1&#x2b;TGFBR1), PSAP-GPR37, MIF- (CD74&#x2b;CXCR4), MIF-(CD74&#x2b;CXCR2), MIF-(CD74<sup>&#x2b;</sup>CD44), CXCL12-CXCR4, and BMP4-(BMPR1B &#x2b; BMPR2) were secreted LR pairs specifically involved in MF2 cells communication with hepatocytes in HCC patients with MVI present (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Potential LR pairs that mediate communication between MF2 cells and hepatocytes. <bold>(A)</bold> Direct contact type LR pairs that mediate communication between MF2 cells and hepatocytes in MV-absent patients. <bold>(B)</bold> Direct contact type LR pairs that mediate communication between MF2 cells and hepatocytes in MVI-present patients. <bold>(C)</bold> Secretory LR pairs mediating the communication between MF2 cells and hepatocytes in patients with MVI absent. <bold>(D)</bold> Secretory LR pairs mediating the communication between MF2 cells and hepatocytes in patients with MVI present.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g003.tif">
<alt-text content-type="machine-generated">Four bubble plots depict cell-cell communications and secreted ligand-receptor pairs interactions between MF2 and hepatocytes, with MVI absent (A, C) and present (B, D). Interaction pairs are listed vertically, with bubble color indicating communication probability and size representing significance (p &#x3C; 0.01). A color gradient bar shows probability range.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-4">
<title>Pseudotime trajectories supported the promoting effect of MF2 cells on MVI formation</title>
<p>To characterize the dynamic changes in gene expression patterns of MF2 cells between MVI-absent and MVI-present samples, differentiation trajectories were constructed using Monocle 2. Most of the MF2 cells at the start of pseudotime were of MVI-absent origin, and MF2 cells of MVI-present origin appeared in pseudotime and were densely clustered at the end of the branch (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Monocle 2 also identified genes that varied with pseudotime (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The correlation between angiogenesis gene sets and TGF-&#x3b2; pathway gene sets was probed, and both angiogenesis and TGF-&#x3b2; pathway showed a significant positive correlation with pseudotime (<xref ref-type="fig" rid="F4">Figures 4C,D</xref>). Therefore, it is speculated that MF2 cells may have a potential promoting effect on MVI formation.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Pseudotime trajectories supported the promoting effect of MF2 cells on MVI formation. <bold>(A)</bold> The pseudotime trajectories of MF2 cells obtained by Monocle&#xa0;2 analysis. <bold>(B)</bold> Genes resulting from Monocle&#xa0;2 analysis that vary with pseudotime. <bold>(C)</bold> Pearson correlation between angiogenic gene sets and pseudotime. <bold>(D)</bold> Pearson correlation analysis between TGF-&#x3b2; pathway gene sets and pseudotime.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g004.tif">
<alt-text content-type="machine-generated">A set of images depicting scientific data analysis includes: (A) a scatter plot showing two components with clusters labeled as MVI absent or MVI present; (B) a heatmap displaying gene expression levels over pseudotime; (C) and (D) scatter plots showing relationships between pseudotime and hallmarks of angiogenesis and TGF Beta signaling, respectively, with correlation coefficients and p-values.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-5">
<title>Genes used as HCC prognosis indicators were identified from MF2 cell markers</title>
<p>The expression of marker genes extracted from MF2 cells was detected in different M stages of the TCGA cohort. The expressions of <italic>CAMK2N1</italic> and <italic>COLEC11</italic> were significantly higher in M1 stage samples than in M0 stage patients (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>). The prognosis of patients in the TCGA cohort was predicted based on <italic>CAMK2N1</italic> and <italic>COLEC11</italic> expression. <italic>CAMK2N1</italic> expression showed a significant correlation with HCC prognosis as observed in the Kaplan&#x2013;Meier curve. The overall survival (OS) of HCC patients with high expression was significantly shorter than that of patients with low expression (<xref ref-type="fig" rid="F5">Figure 5C</xref>). However, no significant correlation between <italic>COLEC11</italic> expression and HCC prognosis was detected in the Kaplan&#x2013;Meier curve obtained by analyzing OS based on <italic>COLEC11</italic> expression (<xref ref-type="fig" rid="F5">Figure 5D</xref>). Therefore, <italic>CAMK2N1</italic> is a potential MF2 cell marker for predicting HCC prognosis.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Genes used as HCC prognosis were identified from MF2 cell markers. <bold>(A)</bold> CAMK2N1 expression differences between M0 stage and M1 stage groups in the TCGA-HCC cohort. <bold>(B)</bold> COLEC11 expression differences between M0 stage and M1 stage groups in the TCGA-HCC cohort. <bold>(C)</bold> Kaplan&#x2013;Meier curves obtained by analyzing the OS of patients in the TCGA-HCC cohort according to CAMK2N1 expression. <bold>(D)</bold> Kaplan&#x2013;Meier curves obtained by analyzing the OS of patients in the TCGA-HCC cohort according to COLEC11 expression.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g005.tif">
<alt-text content-type="machine-generated">Violin plots (A and B) compare expression levels of CAMK2N1 and COLEC11 between groups M0 and M1 with p-values 0.0486 and 0.0405. Kaplan-Meier survival curves (C and D) illustrate the impact of higher and lower expressions of CAMK2N1 and COLEC11 on survival probability over time, with p-values of 0.048 and 0.83, and include risk numbers for different times.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-6">
<title>Cellular validation of HCC prognosis indicators in HCC cells</title>
<p>To explore the potential role of this <italic>CAMK2N1</italic> in HCC, the expression levels of these metrics were first calculated in HCC cells and control cells. We observed lower <italic>CAMK2N1</italic> expression in Huh-7 and HepG2 cells relative to THLE-2 cells (<xref ref-type="fig" rid="F6">Figure 6A</xref>). In addition, to verify the potential effect of this gene on HCC cells, we validated its knockdown in two HCC cell lines (<xref ref-type="fig" rid="F6">Figures 6B,C</xref>). The results of the CCK-8 assay showed that knockdown of the <italic>CAMK2N1</italic> gene significantly increased the proliferation level of Huh-7 and HepG2 cells (<xref ref-type="fig" rid="F6">Figures 6D,E</xref>). Furthermore, <italic>CAMK2N1</italic> gene knockdown also significantly increased the migration and invasion levels of HCC cells (<xref ref-type="fig" rid="F6">Figures 6F&#x2013;I</xref>). These results indicated the scientific rationality of <italic>CAMK2N1</italic>, an MF2 cell marker gene significantly associated with HCC prognosis, as a potential prognostic biomarker.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Cellular validation of HCC prognosis indicators in HCC cells. <bold>(A)</bold> <italic>CAMK2N1</italic> expression in both HCC cells (Huh7 and HepG2) and THLE-2 was assessed using reverse-transcription quantitative PCR. <bold>(B,C)</bold> Validation of the efficiency of <italic>CAMK2N1</italic> knockdown. <bold>(D,E)</bold> CCK-8 assay to evaluate the effect of <italic>CAMK2N1</italic> knockdown on the proliferation level of HCC cells. <bold>(F,G)</bold> Evaluate the effect of <italic>CAMK2N1</italic> gene knockout on cell migration and invasion levels based on Huh-7 cells. <bold>(H,I)</bold> Evaluate the effect of <italic>CAMK2N1</italic> gene knockout on cell migration and invasion levels based on HepG2 cells. Scale bar: 200&#xa0;&#x3bc;m; <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01, <sup>&#x2a;&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.001, and <sup>&#x2a;&#x2a;&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-16-1596181-g006.tif">
<alt-text content-type="machine-generated">Bar graphs (A-C) and line graphs (D-E) show CAMK2N1 mRNA expression and OD450 values in different conditions and time intervals for cell lines THLE-2, Huh-7, and HepG2. Images with bar graphs (F-I) examine cell migration and invasion, depicting wound closure percentages and cell numbers in Huh-7 and HepG2 with si-NC and si-CAMK2N1#1 transfection at 0 hours and 48 hours. Statistical significance is indicated by asterisks.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>MVI is defined by the invasion of cancerous cells into the small blood vessels encircling the liver tumor (<xref ref-type="bibr" rid="B19">Harding-Theobald et al., 2021</xref>). A meta-analysis shows that MVI-positive patients are twice as likely to relapse as MVI-negative patients (<xref ref-type="bibr" rid="B11">Chen et al., 2019</xref>). Microscopically, there is a broad spectrum of MVI (<xref ref-type="bibr" rid="B22">Hwang et al., 2023</xref>). To date, the clear mechanism of MVI in HCC has not been fully elucidated. It is generally accepted that the formation of MVI is a complex process with multi-step regulation, such as the pathological anatomy of cirrhosis, hemodynamics, and tumor molecular biology (<xref ref-type="bibr" rid="B38">Sun et al., 2023</xref>). This study studied the potential cell populations that promote the formation of MVI and the molecular networks that communicate with hepatocytes from the point of view of tumor cell biology and molecular biology, as well as candidate targets that can potentially indicate the prognosis of HCC. This study was the first to demonstrate (<xref ref-type="bibr" rid="B10">Chandarana et al., 2024</xref>): The cellular ecosystem of HCC was rich in hepatocytes, fibroblasts, and immune cells, including myofibroblasts, hepatocytes, proliferative hepatocytes, endothelial cells, dendritic cells, proliferative NK/T cells, plasma B cells, and macrophages (<xref ref-type="bibr" rid="B42">Wang et al., 2023</xref>). The largest proportion difference between MVI-absent patients and MVI-present patients was MFs, which were higher in MVI-present patients and were further divided into five&#xa0;MF subsets (<xref ref-type="bibr" rid="B2">Alawyia and Constantinou, 2023</xref>). Key angiogenesis genes were overexpressed in MF2 cells, and MF2 cells derived from MVI-present patients were enriched at the end of differentiation, which may potentially promote MVI formation. (<xref ref-type="bibr" rid="B3">Bansal et al., 2024</xref>). <italic>CAMK2N1</italic> was a potential MF2 cell marker for predicting the prognosis of HCC. These findings provide novel insights into the cellular and molecular basis of MVI formation in HCC, highlighting MF2 cells as a key pro-angiogenic stromal component that may serve as both a mechanistic driver and a prognostic indicator of vascular invasion.</p>
<p>HCC often occurs in the background of liver fibrosis, and the activation of hepatic stellate cells (HSCs) runs through the whole process of the development of HCC precancerous lesions (<xref ref-type="bibr" rid="B37">Shan et al., 2023</xref>; <xref ref-type="bibr" rid="B46">YOON et al., 2023</xref>). HSCs and their activated derivatives are commonly referred to as MFs (<xref ref-type="bibr" rid="B5">Bogomolova et al., 2024</xref>). The imbalance of MFs is associated with an increased risk of HCC in patients during HCC progression (<xref ref-type="bibr" rid="B16">Filliol et al., 2022</xref>). In the present study, we found that increased MFs in HCC were associated with MVI generation. MF2 is the major MF cluster that promotes the formation of MVI. It is known from previous reports that in TME, HCC cells secrete various soluble factors that are responsible for the phenotypic activation of quiescent HSCs. Tumor cells use activated HSC-derived extracellular matrix (ECM) for migration and invasion (<xref ref-type="bibr" rid="B14">Ezhilarasan and Najimi, 2023</xref>). In this study, we found that MF2 cells were significantly associated with positive regulation of cell proliferation, extracellular matrix organization, angiogenesis, and cell migration. Secretory and direct contact ligand&#x2013;receptor (LR) pairs that mediate the communication between MF2 cells and hepatocytes in HCC patients with MVI present were also identified. Among them, JAG1-NOTCH3 ligand&#x2013;receptor pairing is related to the regulation of phenotypic maturation of vascular smooth muscle cells (<xref ref-type="bibr" rid="B50">Zohorsky et al., 2021</xref>). HSC regulates the differentiation of HPC into hepatocytes through the TGF-&#x3b2;1/Jagged1 signal transduction axis (<xref ref-type="bibr" rid="B1">Aimaiti et al., 2019</xref>). The ITGB2-ICAM1 axis regulates ECM-related features (<xref ref-type="bibr" rid="B27">Li et al., 2023</xref>). Signaling between EFNA5 and EPHA is also involved in mediating biological processes such as angiogenesis and cancer (<xref ref-type="bibr" rid="B23">Irie et al., 2008</xref>). TNFSF12 and its receptor TNFRSF12A are involved in the inflammatory response associated with vascular remodeling (<xref ref-type="bibr" rid="B29">Mendez-Barbero et al., 2019</xref>). CXCL12/CXCR4 promotes ECM production characteristic of fibrosis and induces phenotypic transformation of myofibroblasts (<xref ref-type="bibr" rid="B33">Patalano et al., 2018</xref>). These studies provided favorable evidence that MF2 cells may interact with hepatocytes through these molecular interactions, thereby affecting the ECM or angiogenesis in HCC.</p>
<p>We extracted the marker genes of MF2 cells and identified them as HCC prognostic markers in the TCGA cohort. <italic>CAMK2N1</italic> was identified, which was highly expressed in high M-stage cancers and significantly correlated with poor prognosis of HCC. <italic>CAMK2N1</italic> has been recognized as a tumor suppressor that downregulates the &#x3b2;-catenin/c-Myc oncogenic signaling pathway. Accordingly, Tang et al. discovered that Circ-IP6K2 plays a role in hindering the advancement of renal cell carcinoma by influencing the miR-1292-5p/<italic>CAMK2N1</italic> axis (<xref ref-type="bibr" rid="B39">Tang et al., 2024</xref>). In addition, N6-methyladenosine-induced miR-182-5p was also able to promote multiple myeloma by regulating <italic>CAMK2N1</italic>, which in turn promotes multiple myeloma (<xref ref-type="bibr" rid="B4">Bao et al., 2024</xref>). In previous studies, increased <italic>CAMK2N1</italic> expression has shown an association with increased prostate cancer aggressiveness (<xref ref-type="bibr" rid="B9">Carneiro et al., 2019</xref>). However, Peng et al. showed that <italic>CAMK2NA</italic> is a 1p36 tumor suppressor gene, and silencing and ectopic expression of <italic>CAMK2N1</italic> enhanced and inhibited cell proliferation, colony formation, and xenograft tumor growth, respectively, in HCC nude mice (<xref ref-type="bibr" rid="B34">Peng et al., 2021</xref>). We suspect that the reasons for these differences include tumor heterogeneity and differences in the number of samples studied.</p>
<p>Our study has some limitations. For example, the scRNA-seq data used in this study had a small sample size and may have inter-individual biological differences, limiting the generalizability of conclusions on the association between cell subpopulation proportions and MVI. In the future, more independent cohorts and multi-center scRNA-seq data can be combined for integrated analysis to enhance the robustness and broad applicability of the results. Meanwhile, the ability to analyze cell distribution and heterogeneity can be further enhanced by spatial transcriptome technology. In addition, this study focuses on the effect of the MF2 cell subpopulation on MVI, and although the strategy is clearly focused, the synergistic effect of other microenvironmental cells on MVI formation may be missed. For this reason, subsequent studies will combine cellular communication networks, jointly analyze other key cell subpopulations, and construct a model of MVI formation driven by multi-cell interactions to more comprehensively understand the synergistic mechanisms in the tumor microenvironment. Finally, although the study revealed major cell subpopulations, cell types of potential functional significance in the tumor microenvironment were not stably identified due to technical limitations or sparse data, and some important regulatory networks may have been missed. Therefore, we will further optimize the tissue processing and library construction strategies to enhance the capture of rare cell populations and combine protein markers to improve the accuracy of cell identification.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>In summary, this study reported cellular heterogeneity between HCC patients with MVI absent and MVI present, demonstrated the role and underlying mechanism of MFs in promoting MVI formation, and provided CAMK2N1 as a target in MF markers for HCC prognosis.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>XL: Writing &#x2013; review and editing, Supervision, Software, Writing &#x2013; original draft, Data curation, Conceptualization, Resources, Visualization, Project administration. JP: Writing &#x2013; review and editing, Investigation, Software, Methodology, Formal analysis, Project administration, Data curation. LW: Visualization, Project administration, Resources, Supervision, Methodology, Software, Writing &#x2013; original draft. QX: Conceptualization, Visualization, Resources, Formal analysis, Data curation, Software, Writing &#x2013; review and editing. TF: Data curation, Validation, Investigation, Resources, Writing &#x2013; review and editing, Formal analysis, Visualization. QW: Resources, Writing &#x2013; original draft, Writing &#x2013; review and editing, Visualization, Formal analysis, Validation, Methodology, Conceptualization.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This study has received funding from the Medical Science Research Project of Hebei (grant number 20240769).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>DEG, differentially expressed gene; GO, Gene Ontology; HCC, hepatocellular carcinoma; MF, myofibroblast; MVI, microvascular invasion; PCA, principal component analysis; PPI, protein&#x2013;protein interaction; ScRNA-seq, single-cell RNA sequencing; TCGA, The Cancer Genome Atlas.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aimaiti</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Hepatic stellate cells regulate hepatic progenitor cells differentiation <italic>via</italic> the TGF-&#x3b2;1/Jagged1 signaling axis</article-title>. <source>J. Cell Physiol.</source> <volume>234</volume> (<issue>6</issue>), <fpage>9283</fpage>&#x2013;<lpage>9296</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27609</pub-id>
<pub-id pub-id-type="pmid">30317614</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alawyia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Constantinou</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Hepatocellular carcinoma: a narrative review on current knowledge and future prospects</article-title>. <source>Curr. Treat. Options Oncol.</source> <volume>24</volume> (<issue>7</issue>), <fpage>711</fpage>&#x2013;<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1007/s11864-023-01098-9</pub-id>
<pub-id pub-id-type="pmid">37103744</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bansal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Burman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vachher</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Decoding glycobiomarkers in non-alcoholic steatohepatitis (NASH) and related hepatocellular carcinoma (HCC)</article-title>. <source>Curr. Proteomics</source> <volume>22</volume>. <pub-id pub-id-type="doi">10.2174/0115701646341608241025030547</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1</article-title>. <source>Mol. Cell. Biochem.</source> <volume>479</volume> (<issue>11</issue>), <fpage>3077</fpage>&#x2013;<lpage>3089</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-023-04906-w</pub-id>
<pub-id pub-id-type="pmid">38180718</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogomolova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Balakrishnan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The good, the bad and the ugly - about diverse phenotypes of hepatic stellate cells in the liver</article-title>. <source>Cell Mol. Gastroenterol. Hepatol.</source> <volume>17</volume>, <fpage>607</fpage>&#x2013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2024.01.002</pub-id>
<pub-id pub-id-type="pmid">38216053</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruix</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Merle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Granito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Bodoky</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet London, Engl.</source> <volume>389</volume> (<issue>10064</issue>), <fpage>56</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32453-9</pub-id>
<pub-id pub-id-type="pmid">27932229</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smibert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Papalexi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Satija</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Integrating single-cell transcriptomic data across different conditions, technologies, and species</article-title>. <source>Nat. Biotechnol.</source> <volume>36</volume> (<issue>5</issue>), <fpage>411</fpage>&#x2013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.4096</pub-id>
<pub-id pub-id-type="pmid">29608179</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y. U. E.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L. I. N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Hepatitis B virus X protein-mediated upregulation of miR-221 activates the CXCL12-CXCR4 axis to promote NKT cells in HBV-Related hepatocellular carcinoma</article-title>. <source>Biocell</source> <volume>47</volume> (<issue>7</issue>), <fpage>1537</fpage>&#x2013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.32604/biocell.2023.027205</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carneiro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Quintela-Vieira</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moreira-Barbosa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>F. D.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>A. T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Expression of EMT-related genes CAMK2N1 and WNT5A is increased in locally invasive and metastatic prostate cancer</article-title>. <source>J. Cancer</source> <volume>10</volume> (<issue>24</issue>), <fpage>5915</fpage>&#x2013;<lpage>5925</lpage>. <pub-id pub-id-type="doi">10.7150/jca.34564</pub-id>
<pub-id pub-id-type="pmid">31762801</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandarana</surname>
<given-names>C. V.</given-names>
</name>
<name>
<surname>Mithani</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D. V.</given-names>
</name>
<name>
<surname>Kikani</surname>
<given-names>U. B.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Vibrational spectrophotometry: a comprehensive review on the diagnosis of gastric and liver cancer</article-title>. <source>Curr. Pharm. Anal.</source> <volume>20</volume> (<issue>7</issue>), <fpage>453</fpage>&#x2013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.2174/0115734129322567240821052326</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J. X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W. X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis</article-title>. <source>HPB Oxf.</source> <volume>21</volume> (<issue>8</issue>), <fpage>935</fpage>&#x2013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.1016/j.hpb.2019.02.003</pub-id>
<pub-id pub-id-type="pmid">30871805</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dayoub</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Buerger</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Melter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Augmenter of liver regeneration (ALR) exhibits a dual signaling impact on hepatic acute-phase response</article-title>. <source>Exp. Mol. Pathol.</source> <volume>102</volume> (<issue>3</issue>), <fpage>428</fpage>&#x2013;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexmp.2017.05.011</pub-id>
<pub-id pub-id-type="pmid">28506765</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dennis</surname>
<given-names>G.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Hosack</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>H. C.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>DAVID: database for annotation, visualization, and integrated discovery</article-title>. <source>Genome Biol.</source> <volume>4</volume> (<issue>5</issue>), <fpage>R60</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2003-4-9-r60</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezhilarasan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Najimi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver</article-title>. <source>Crit. Rev. Oncol. Hematol.</source> <volume>182</volume>, <fpage>103902</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2022.103902</pub-id>
<pub-id pub-id-type="pmid">36621514</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Federico</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Giunta</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Tufo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tovoli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Petrillo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Daniele</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Resistance to antiangiogenic therapy in hepatocellular carcinoma: from molecular mechanisms to clinical impact</article-title>. <source>Cancers (Basel)</source> <volume>14</volume> (<issue>24</issue>), <fpage>6245</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14246245</pub-id>
<pub-id pub-id-type="pmid">36551730</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filliol</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dapito</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L. X.</given-names>
</name>
<name>
<surname>Ravichandra</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis</article-title>. <source>Nature</source> <volume>610</volume> (<issue>7931</issue>), <fpage>356</fpage>&#x2013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05289-6</pub-id>
<pub-id pub-id-type="pmid">36198802</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finn</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galle</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Ducreux</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma</article-title>. <source>N. Engl. J. Med.</source> <volume>382</volume> (<issue>20</issue>), <fpage>1894</fpage>&#x2013;<lpage>1905</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1915745</pub-id>
<pub-id pub-id-type="pmid">32402160</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gouw</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Balabaud</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kusano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Todo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ichida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kojiro</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?</article-title> <source>Liver Transpl.</source> <volume>17</volume> (<issue>Suppl. 2</issue>), <fpage>S72</fpage>&#x2013;<lpage>S80</lpage>. <pub-id pub-id-type="doi">10.1002/lt.22368</pub-id>
<pub-id pub-id-type="pmid">21714066</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding-Theobald</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Louissaint</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Maraj</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cuaresma</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mendiratta-Lala</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma</article-title>. <source>Aliment. Pharmacol. Ther.</source> <volume>54</volume> (<issue>7</issue>), <fpage>890</fpage>&#x2013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1111/apt.16563</pub-id>
<pub-id pub-id-type="pmid">34390014</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hensvold</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Horuluoglu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sahlstrom</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thyagarajan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Diaz Boada</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The human bone marrow plasma cell compartment in rheumatoid arthritis - clonal relationships and anti-citrulline autoantibody producing cells</article-title>. <source>J. Autoimmun.</source> <volume>136</volume>, <fpage>103022</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2023.103022</pub-id>
<pub-id pub-id-type="pmid">37001434</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data</article-title>. <source>Nucleic Acids Res.</source> <volume>51</volume> (<issue>D1</issue>), <fpage>D870</fpage>&#x2013;<lpage>D876</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac947</pub-id>
<pub-id pub-id-type="pmid">36300619</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging</article-title>. <source>Clin. Mol. Hepatol.</source> <volume>29</volume> (<issue>3</issue>), <fpage>733</fpage>&#x2013;<lpage>746</lpage>. <pub-id pub-id-type="doi">10.3350/cmh.2023.0034</pub-id>
<pub-id pub-id-type="pmid">37157775</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irie</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Okuno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pasquale</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Heparan sulfate regulates ephrin-A3/EphA receptor signaling</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>105</volume> (<issue>34</issue>), <fpage>12307</fpage>&#x2013;<lpage>12312</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0801302105</pub-id>
<pub-id pub-id-type="pmid">18715996</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guerrero-Juarez</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kuan</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inference and analysis of cell-cell communication using CellChat</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>1088</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-21246-9</pub-id>
<pub-id pub-id-type="pmid">33597522</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korsunsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Millard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Slowikowski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Fast, sensitive and accurate integration of single-cell data with harmony</article-title>. <source>Nat. methods</source> <volume>16</volume> (<issue>12</issue>), <fpage>1289</fpage>&#x2013;<lpage>1296</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id>
<pub-id pub-id-type="pmid">31740819</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ueshima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Minami</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chishina</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh A liver function: a proof-of-concept study</article-title>. <source>Cancers (Basel)</source> <volume>11</volume> (<issue>8</issue>), <fpage>1084</fpage>. <pub-id pub-id-type="doi">10.3390/cancers11081084</pub-id>
<pub-id pub-id-type="pmid">31370183</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>ITGB2-ICAM1 axis promotes liver metastasis in BAP1-mutated uveal melanoma with retained hypoxia and ECM signatures</article-title>. <source>Cell Oncol. (Dordr)</source> <volume>47</volume>, <fpage>951</fpage>&#x2013;<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1007/s13402-023-00908-4</pub-id>
<pub-id pub-id-type="pmid">38150154</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>T. D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title>. <source>Methods San Diego, Calif.</source> <volume>25</volume> (<issue>4</issue>), <fpage>402</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
<pub-id pub-id-type="pmid">11846609</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez-Barbero</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gutierrez-Munoz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Madrigal-Matute</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Minguez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Egido</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>J. B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis</article-title>. <source>EBioMedicine</source> <volume>46</volume>, <fpage>274</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.07.072</pub-id>
<pub-id pub-id-type="pmid">31395500</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Immunosuppressive CD10(&#x2b;)ALPL(&#x2b;) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells</article-title>. <source>J. hepatology</source> <volume>79</volume> (<issue>6</issue>), <fpage>1435</fpage>&#x2013;<lpage>1449</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2023.08.024</pub-id>
<pub-id pub-id-type="pmid">37689322</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nitta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Allard</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Sebagh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciacio</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Pittau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vibert</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Prognostic value and prediction of extratumoral microvascular invasion for hepatocellular carcinoma</article-title>. <source>Ann. Surg. Oncol.</source> <volume>26</volume> (<issue>8</issue>), <fpage>2568</fpage>&#x2013;<lpage>2576</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-019-07365-0</pub-id>
<pub-id pub-id-type="pmid">31054040</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohara</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Recent progress in type 1 classical dendritic cell cross-presentation - cytosolic, vacuolar, or both?</article-title> <source>Curr. Opin. Immunol.</source> <volume>83</volume>, <fpage>102350</fpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2023.102350</pub-id>
<pub-id pub-id-type="pmid">37276818</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patalano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodriguez-Nieves</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Colaneri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cotellessa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Almanza</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhilin-Roth</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>CXCL12/CXCR4-Mediated procollagen secretion is coupled to Cullin-RING ubiquitin ligase activation</article-title>. <source>Sci. Rep.</source> <volume>8</volume> (<issue>1</issue>), <fpage>3499</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-21506-7</pub-id>
<pub-id pub-id-type="pmid">29472636</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling</article-title>. <source>Cancer Lett.</source> <volume>497</volume>, <fpage>66</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2020.10.017</pub-id>
<pub-id pub-id-type="pmid">33068700</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pliner</surname>
<given-names>H. A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Reversed graph embedding resolves complex single-cell trajectories</article-title>. <source>Nat. methods</source> <volume>14</volume> (<issue>10</issue>), <fpage>979</fpage>&#x2013;<lpage>982</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4402</pub-id>
<pub-id pub-id-type="pmid">28825705</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Peralvarez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luong</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Andreana</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dhillon</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Burroughs</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability</article-title>. <source>Ann. Surg. Oncol.</source> <volume>20</volume> (<issue>1</issue>), <fpage>325</fpage>&#x2013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-012-2513-1</pub-id>
<pub-id pub-id-type="pmid">23149850</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>New insights into fibrotic signaling in hepatocellular carcinoma</article-title>. <source>Front. Oncol.</source> <volume>13</volume>, <fpage>1196298</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1196298</pub-id>
<pub-id pub-id-type="pmid">38074679</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>E. J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Circulating tumor cells participate in the formation of microvascular invasion and impact on clinical outcomes in hepatocellular carcinoma</article-title>. <source>Front. Genet.</source> <volume>14</volume>, <fpage>1265866</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2023.1265866</pub-id>
<pub-id pub-id-type="pmid">38028589</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q. J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. R.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma</article-title>. <source>Funct. and Integr. genomics</source> <volume>24</volume> (<issue>4</issue>), <fpage>122</fpage>. <pub-id pub-id-type="doi">10.1007/s10142-024-01398-9</pub-id>
<pub-id pub-id-type="pmid">38980439</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Emerging and innovative Theranostic approaches for mesoporous silica nanoparticles in hepatocellular carcinoma: current status and advances</article-title>. <source>Front. Bioeng. Biotechnol.</source> <volume>8</volume>, <fpage>184</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2020.00184</pub-id>
<pub-id pub-id-type="pmid">32211399</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Idilman</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Akata</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ozmen</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Karcaaltincaba</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Microvascular invasion in hepatocellular carcinoma</article-title>. <source>Diagn Interv. Radiol.</source> <volume>22</volume> (<issue>2</issue>), <fpage>125</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.5152/dir.2015.15125</pub-id>
<pub-id pub-id-type="pmid">26782155</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>IMMT promotes hepatocellular carcinoma formation <italic>via</italic> PI3K/AKT/mTOR pathway</article-title>. <source>Oncologie</source> <volume>25</volume> (<issue>6</issue>), <fpage>691</fpage>&#x2013;<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1515/oncologie-2023-0289</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>iTRAQ-based proteomic analysis unveils NCAM1 as a novel regulator in doxorubicin-induced cardiotoxicity and DT-010-exerted cardioprotection</article-title>. <source>Curr. Pharm. Anal.</source> <volume>20</volume> (<issue>9</issue>), <fpage>966</fpage>&#x2013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.2174/0115734129331758241022113026</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dura</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>
<italic>Ex vivo</italic> dynamics of human glioblastoma cells in a Microvasculature-on-a-Chip system correlates with tumor heterogeneity and subtypes</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>6</volume> (<issue>8</issue>), <fpage>1801531</fpage>. <pub-id pub-id-type="doi">10.1002/advs.201801531</pub-id>
<pub-id pub-id-type="pmid">31016107</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Single-nucleus RNA sequencing reveals cardiac macrophage landscape in hypoplastic left heart syndrome</article-title>. <source>Congenit. Heart Dis.</source> <volume>19</volume> (<issue>2</issue>), <fpage>233</fpage>&#x2013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.32604/chd.2024.050231</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saima</surname>
<given-names>F.-T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Baik</surname>
<given-names>S.-K.</given-names>
</name>
<name>
<surname>Eom</surname>
<given-names>Y.-W.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>AKT regulates IL-1&#x3b2;-induced proliferation and activation of hepatic stellate cells</article-title>. <source>BIOCELL</source> <volume>47</volume> (<issue>3</issue>), <fpage>669</fpage>&#x2013;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.32604/biocell.2023.025365</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Upregulation of LncRNA WT1-AS inhibits tumor growth and promotes autophagy in gastric cancer <italic>via</italic> suppression of PI3K/Akt/mTOR pathway</article-title>. <source>Curr. Mol. Pharmacol.</source> <volume>17</volume>, <fpage>e18761429318398</fpage>. <pub-id pub-id-type="doi">10.2174/0118761429318398240918063450</pub-id>
<pub-id pub-id-type="pmid">39592900</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q. P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>TED: two-Stage expert-guided interpretable diagnosis framework for microvascular invasion in hepatocellular carcinoma</article-title>. <source>Med. Image Anal.</source> <volume>82</volume>, <fpage>102575</fpage>. <pub-id pub-id-type="doi">10.1016/j.media.2022.102575</pub-id>
<pub-id pub-id-type="pmid">36063747</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>M2 macrophage-related gene signature in chronic rhinosinusitis with nasal polyps</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1047930</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1047930</pub-id>
<pub-id pub-id-type="pmid">36466903</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zohorsky</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mequanint</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Immobilization of Jagged1 enhances vascular smooth muscle cells maturation by activating the notch pathway</article-title>. <source>Cells</source> <volume>10</volume> (<issue>8</issue>), <fpage>2089</fpage>. <pub-id pub-id-type="doi">10.3390/cells10082089</pub-id>
<pub-id pub-id-type="pmid">34440858</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zulibiya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Single-cell RNA sequencing reveals potential for endothelial-to-mesenchymal transition in tetralogy of fallot</article-title>. <source>Congenit. Heart Dis.</source> <volume>18</volume> (<issue>6</issue>), <fpage>611</fpage>&#x2013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.32604/chd.2023.047689</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>